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Background: High-mobility group box 1 (HMGB1) is a nucleoprotein that is related to inflammation. It has been
implicated in a variety of biologically important processes, including transcription, DNA repair, differentiation,
development, and extracellular signaling. Recently, its important role in the process of tumor invasion, metastasis, and
resistance to anti-cancer therapies has been demonstrated. In this study, we aimed to investigate the correlation of
HMGB1 expression and resistance of rectal cancer patients to chemoradiotherapy (CRT) prior to curative operation.
Methods: We retrospectively reviewed the data of 75 lower rectal cancer patients without complete pathological
response who had received preoperative CRT and had undergone curative resection at the University of Tokyo
Hospital between May 2003 and June 2010. HMGB1 expression in surgically resected specimens was evaluated using
immunohistochemical detection and specimens were classified into high or low HMGB1 expression groups.
Clinicopathologic features, degree of tumor reduction, regression of tumor grade, and patient survival were compared
between the groups using non-paired Student’s t-tests and Kaplan-Meier analysis.
Results: A total of 52 (69.3%) patients had high HMGB1 expression, and 23 (30.7%) had low expression. HMGB1
expression was significantly correlated with histologic type (P = 0.02), lymphatic invasion (P = 0.02), and venous invasion
(P = 0.05). Compared to patients with low HMGB1 expression, those with high expression had a poorer response to
CRT, in terms of tumor reduction ratio (42.2 versus 28.9%, respectively; P <0.01) and post-CRT histological tumor
regression grade (56.5 versus 30.8% grade 2; respectively; P = 0.03). However, no significant correlation was
found between HMGB1 expression and recurrence-free and overall survival rates.
Conclusions: HMGB1 expression may be one of the key factors regulating the response of rectal cancer to
preoperative CRT in terms of tumor invasiveness and resistance to therapy.
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Table 1 Grade of tumor regression after
chemoradiotherapy for rectal carcinoma
Grade Tumor regression
Grade 0 Neither necrosis nor regressive change
Grade 1 a >2/3 vital residual tumor cells
b Approximately 1/3 to 2/3 vital residual tumor cells
Grade 2 <1/3 vital residual tumor cells
Grade 3 No vital residual tumor cells
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High-mobility group box 1 (HMGB1) was first identified
as a nuclear chromatin-binding protein that plays signifi-
cant roles in various biologically important processes,
including transcription, DNA repair, differentiation, and
development [1]. In addition to its biological functions
in the nuclear compartment, HMGB1 functions as an
extracellular signaling molecule during inflammation,
cell differentiation, cell migration, and metastasis [2-6].
HMGB1 is reported to be actively secreted by inflamma-
tory cells when stimulated by endotoxin, tumor necrosis
factor-α (TNF-α), or interleukin-1β (IL-1β), and is also
passively released from necrotic cells [7,8]. HMGB1 pro-
motes inflammation by binding to the receptors, such as
the receptor for advanced glycation end-products (RAGE),
Toll-like receptor (TLR) 2, and TLR-4, which are
expressed in a variety of cells including monocytes,
macrophages, and endothelial cells [7,9-12]. Through
these actions, HMGB1 has been implicated in the
pathogenesis of various clinical conditions, including
sepsis [13], ischemia-reperfusion [14], meningitis [15],
neurodegeneration [16], aging [17], and cancer [5,6,18].
In the pathophysiology of cancer, increased expression
of HMGB1 and RAGE is associated with proliferative ac-
tivity and metastatic potential in many types of tumors,
including breast cancer [19], hepatocellular carcinoma
[8], melanoma [20], glioma [21,22], prostate cancer [23],
gastric cancer [24], and colorectal cancer [25-27]. In-
creased RAGE-HMGB1 activity induces phosphorylation
of extracellular signal-related kinase (ERK) [28], activat-
ing GTPases of the Rho family [29]. Thus, it contributes
to cancer development through different mechanisms,
including angiogenesis [28], cell migration [30], and
apoptosis inhibition [24]. Moreover, extracellular redu-
cible HMGB1 has been shown to induce autophagy and
promote tumor resistance to alkylators, tubulin disrupt-
ing agents, DNA cross-linkers, and DNA intercalators in
human pancreatic cancer and colon cancer cell lines [31].
Chemotherapy-induced HMGB1 expression in osteosar-
coma cells promotes autophagy to inhibit apoptosis and
increase drug resistance [32]. However, HMGB1 has a
paradoxical dual effect on tumors [6]. HMGB1 has been
shown to stimulate mature dendritic cells to degrade
tumor antigen processing through its interaction with
TLR-4 [33]. Furthermore, it mediates endogenous TLR-2
activation, resulting in tumor regression [34]. Therefore,
the role of HMGB1 in cancer development and progres-
sion, as well as its effect on the response to treatment,
remains largely unexplored.
Colorectal cancer is a highly invasive and metastatic
tumor, and mortality associated with this cancer has in-
creased worldwide recently [35]. Surgical resection and
combined modality therapy, including chemotherapy,
radiotherapy, and chemoradiotherapy (CRT), are themain therapeutic strategies for the management of rectal
cancer. However, the effectiveness of these therapies
greatly varies among patients, and those with a weaker re-
sponse have a worse prognosis. In particular, those who do
not respond to neoadjuvant CRT have a poor prognosis
[36]. Thus, analysis of the molecular mechanisms under-
lying the resistance of rectal cancer cells to CRT is essential
for the development of novel treatment strategies for the
disease. In this study, we performed immunohistochemical
analyses to examine HMGB1 expression in surgically
resected specimens of rectal cancer after preoperative
CRT and investigated its association with clinicopathologi-
cal features, in an attempt to elucidate the possible associ-
ation between HMGB1 expression and resistance to CRT.
Methods
Patients and evaluation of response to
chemoradiotherapy
A total of 82 patients with lower rectal cancer who
had received preoperative CRT and undergone curative
resection at the University of Tokyo Hospital between
May 2003 and June 2010 were enrolled. Patients receiv-
ing CRT had cancer in the middle or lower part of the
rectum, with tumor invading further than the muscularis
propria. CRT consisted of radiotherapy (1.8 Gy × 28
fractions = 50.4 Gy irradiation) and chemotherapy with
a 5-fluorouracil (FU) prodrug (300 mg/m2/day) and
leucovorin (75 mg/day), administered orally during the
entire course of radiotherapy. We excluded seven pa-
tients with complete pathological response after CRT
because in this study, we aimed to evaluate the residual
cancer cells by immunohistochemical staining. Thus,
among the 82 patients, 75 were considered eligible,
and HMGB1 expression in surgically resected speci-
mens was evaluated using immunohistochemical ana-
lyses. Clinicopathological features were analyzed on
the basis of the TNM Classification of Malignant Tu-
mors, Seventh edition, using the International Union
Against Cancer (UICC) [37] and World Health Organization
(WHO) histological criteria [38]. Post-CRT histological
tumor regression was graded according to the seventh
edition of the Japanese Guidelines for Clinical and
Pathological Studies on Carcinoma of the Colorectum
(Table 1) [39]. In this study, both grade 1a and 1b were
(a)
(b)
Figure 1 HMGB1 Immunohistochemical staining of lower rectal
carcinoma treated with chemoradiotherapy. (a) High HMGB1
expression (original magnification, ×200). HMGB1 is predominant in
the nuclei of tumor cells, and shows diffuse and strong expression.
(b) Tumors with low HMGB1 expression (original magnification,
×200). HMGB1 expression is observed in focal tumor cells.
Hongo et al. World Journal of Surgical Oncology 2015, 13:7 Page 3 of 7
http://www.wjso.com/content/13/1/7classified together as grade 1. The reduction ratio was
calculated based on the results of barium enema X-ray
examination performed before and after CRT. The
largest dimension of the tumor, from the same angle,
before, and after CRT, was measured, and the post- to
pre-CRT ratio was calculated. Patients’ consent and
approval of the Ethics Committee of the University of
Tokyo were obtained for the use of clinical samples for
research purposes.
Immunohistochemical evaluation
Consecutive formalin-fixed paraffin-embedded 4-μm sec-
tions were used for the immunohistochemical evaluation.
After treatment with xylene and ethanol, followed by
washing with phosphate-buffered saline (PBS), tumor
specimens were subjected to heat-induced antigen re-
trieval in citrate buffer (Muto Pure Chemicals Co., Ltd,
Tokyo, Japan). After washing with PBS, endogenous
peroxidase was blocked with 3% hydrogen peroxide so-
lution in methanol for 15 minutes (Junsei Chemical
Co.Ltd, Tokyo, Japan). The tissues were then washed
with PBS and were incubated with 5% bovine serum al-
bumin (BSA) (Sigma Aldrich Chemical Co., St. Louis,
Missouri, United States) for 30 minutes to block non-
specific antibody binding. The slides were then incu-
bated overnight at 4°C with monoclonal antibodies against
HMGB1 (Sigma Aldrich Chemical Co., St. Louis, Missouri,
United States) at a dilution of 1:300. After washing three
times with PBS, and incubation with biotinylated rabbit anti-
mouse immunoglobulin-labeled globulin (Nichirei, Tokyo,
Japan) for 20 minutes, Meyer’s hematoxylin (Sigma Aldrich
Chemical Co., St. Louis, Missouri, United States) was used
for counterstaining. One field per specimen, from an opti-
mally stained area at a magnification of × 400, was randomly
selected for evaluation. HMGB1 expression was strongly and
predominantly detected in the nuclei of cancer cells, and it
was also weakly observed in the cytoplasm of a few cases
(Figure 1). Specimens were classified into high or low
HMGB1 expression groups, according to their expression in
residual cancer cells. When diffuse HMGB1 staining in the
nuclei of residual cancer cells was observed, it was consid-
ered as high HMGB1 expression (Figure 1a), and when
staining was only observed focally, it was considered as low
expression (Figure 1b). Staining was evaluated independently
by two observers trained in pathology (KH and SK) who
were unaware of the clinical findings. Discrepancies between
their findings were resolved by discussion. The correlations
between HMGB1 expression and clinicopathological fea-
tures, tumor recurrence-free survival, and overall survival
rates were analyzed.
Statistical analysis
The statistical significance of differences was evaluated
using non-paired Student’s t-test, as appropriate. Anassociation was considered significant when the exact
significance level of the test was less than 0.05. Actuarial
overall survival and recurrence-free rates were analyzed
using the Kaplan-Meier method. The significance of sev-
eral variables of the tumor regression grade after CRT




The clinicopathological findings of the 75 patients with
lower rectal cancer who had received preoperative CRT
and undergone surgical resection are listed in Table 2. A
total of 45 patients (60.0%) were male, and 30 (40.0%)
were female, with an age range of 33 to 79 years (mean
61.4 ± 10.2 years). There were 23 (30.7%) patients with
stage 1 lower rectal cancer, 32 (42.7%) with stage 2, 13
(17.4%) with stage 3, and 7 (9.3%) with stage 4. According
Table 2 Characteristics of rectal cancer patients in this
study
Characteristics
Age: mean age (years) ± SD 61.4 ± 10.2
Gender M 45 (60.0%)
F 30 (40.0%)
Tumor size (mm) ± SE 45.4 ± 8.6








Lymphatic invasion Positive 7 (9.3%)
Negative 68 (90.7%)
Venous invasion Positive 39 (52.0%)
Negative 36 (48.0%)
Lymph node metastasis Positive 15 (20.0%)
Negative 60 (80.0%)
Distant metastasis Positive 2 (1.3%)
Negative 152 (98.7%)
Liver metastasis Positive 1 (0.6%)
Negative 153 (99.4%)




Tumor regression grade 1 46 (61.3%)
2 29 (38.7%)
Reduction ratio (%) ± SD 33.0 ± 16.1
*TNM Classification of Malignant Tumors, seventh edition. **World Health
Organization (WHO) histological criteria.
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and 29 (38.7%) were grade 2. The average reduction ratio
after CRT was 33.0 ± 16.1%.
Correlation between clinicopathological features and
HMGB1 expression in rectal cancer patients treated with
chemoradiotherapy
The correlation between HMGB1 expression and the
clinicopathological characteristics of tumors is shown in
Table 3. A total of 52 (69.3%) patients had high HMGB1
expression, and 23 (30.7%) had low expression. No cor-
relation was found between HMGB1 expression and age,
gender, tumor size, depth of tumor, lymph node metastasis,
and TNM stage. However, HMGB1 expression significantlycorrelated with the histological type of the tumor (P = 0.02),
lymphatic invasion (P= 0.02), and venous invasion (P=
0.05). Well-differentiated tumors were observed in 87% (20
out of 23) of tumors with low HMGB1 expression and
55.8% (29 out of 52) of tumors with high expression (P=
0.02). Lymphatic invasion was identified in 13.5% (seven out
of 52) of tumors with high HMGB1 expression, but in no
cases with low HMGB1 (P= 0.02). Venous invasion was
present in 59.6% (31 out of 52) of tumors with high HMGB1
expression compared to 34.8% (eight out of 23) of those
with low expression (P = 0.05). Moreover, compared to low
expression, high HMGB1 expression was associated with a
poorer response to CRT, in terms of both the tumor reduc-
tion ratio (42.2 versus 28.9%, respectively; P <0.01) and the
post-CRT histological tumor regression grade (43.5 versus
69.2% and 56.5 versus 30.8%, respectively for grades 1 and 2;
P= 0.03).
Recurrence-free survival and overall survival analysis of
rectal cancer patients in relation to HMGB1 expression
Using Kaplan-Meier analysis, the log-rank test revealed
no significant correlation between the expression of
HMGB1 and recurrence-free survival, overall survival
(Figure 2a, b), and local recurrence (data not shown).
Discussion
HMGB1 is both a nuclear factor and a secreted protein
that acts as a damage-associated molecular pattern mol-
ecule (DAMP) [40]. Recently, HMGB1 has been shown
to play an important role in cancer biology, including
angiogenesis, apoptosis, growth signals, tissue invasion,
and metastasis [41-43]. In this study, we focused on the
HMGB1 staining pattern in the nuclear compartment,
but not the cytoplasm, of rectal cancer cells, and evalu-
ated its possible role in tumor progression and resistance
to treatment.
In our series, HMGB1 expression significantly corre-
lated with the histological type of tumor, lymphatic inva-
sion, and venous invasion in rectal cancer. Patients with
high HMGB1 expression were more resistant to CRT, as
revealed by lower tumor reduction ratio and lower post-
CRT histological tumor regression grade. This may imply
that rectal cancers with high HMGB1 expression have
higher malignancy potential, acquiring resistance to CRT.
Corroborating these findings, we observed that HMGB1
expression significantly correlated with lymphatic and
venous invasion. In oral cancer, HMGB1 has been re-
ported to promote lymphangiogenesis through the upreg-
ulation of vascular endothelial growth factor C (VEGF-C)
and vascular endothelial growth factor D (VEGF-D) [44],
which might be linked to the transmigration of HMGB1
[27]. Furthermore, in nasopharyngeal carcinoma cells,
endogenous HMGB1 expression was associated with
invasiveness [41].
Table 3 Correlation between the clinicopathologic features and HMGB1 expression
Characteristics HMGB1 HMGB1 P value
High expression Low expression
52 (69.3%) 23 (30.7%)
Age: mean ± SD (years) 61.6 ± 10.3 61.1 ± 10.2 0.87
Gender M 30 (57.7%) 15 (65.2%) 0.54
F 22 (42.3%) 8 (34.8%)
Tumor size (mm) ± SE 5.35 ± 1.02 2.72 ± 1.53 0.16
Depth of tumor* T1 5 (9.6%) 2 (8.7%) 0.55
T2 12 (23.1%) 9 (39.1%)
T3 31 (59.6%) 11 (47.8%)
T4 4 (7.7%) 1 (4.4%)
Lymph node metastasis Positive 13 (25.0%) 2 (8.7%) 0.08
Negative 39 (75.0%) 21 (91.3%)
Histologic type** Well 29 (55.8%) 20 (87.0%) 0.02
Moderate 21 (40.4%) 3 (13.0%)
Mucinous 2 (3.9%) 0 (0%)
Lymphatic invasion Positive 7 (13.5%) 0 (0%) 0.02
Negative 45 (86.5%) 23 (100%)
Venous invasion Positive 31 (59.6%) 8 (34.8%) 0.05
Negative 21 (40.4%) 15 (65.2%)
Tumor regression grade 1 36 (69.2%) 10 (43.5%) 0.03
2 16 (30.8%) 13 (56.5%)
Reduction ratio (%) ± SD 28.9 ± 2.1 42.2 ± 3.1 0
Stage** 1 14 (26.9%) 9 (39.1%) 0.22
2 21 (40.4%) 11 (47.8%)
3 11 (21.1%) 2 (8.7%)
4 6 (11.5%) 1 (4.4%)
*TNM Classification of Malignant Tumors, seventh edition. **World Health Organization (WHO) histological criteria.












HMGB-1(high expression) HMGB-1(low expression)
a Overall survival   
(P=0.24)
Disease free survival 
(P=0.52)
b 
Figure 2 Recurrence-free survival and overall survival analysis of colon cancer patients in relation to HMGB-1 expression. (a) Overall survival
rates. (b) Kaplan-Meier plot showing disease-free survival rates of rectal cancer patients receiving preoperative chemoradiotherapy.
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radiotherapy and chemotherapy by HMGB1 may be: 1)
the facilitation of protein-protein interaction and recog-
nition of DNA damage in the process of mismatch repair
[45]; 2) regulation of autophagy [31]; and 3) regulation
of heat shock protein beta-1 (HSPB1) gene expression,
which regulates mitophagy [46]. After DNA damage
induced by ultraviolet light irradiation or platination,
HMGB1 is sequestered in the nucleus, which is classic-
ally associated with apoptosis [8]. An increased level of
HMGB1 might promote DNA repair induced by radi-
ation. In addition, HMGB1 is a critical regulator of au-
tophagy [31], promoting drug resistance in osteosarcoma
[32] and leukemia cells [47]. Chemotherapy-induced
HMGB1 expression in osteosarcoma cells promoted au-
tophagy through controlling the formation of the Beclin
1-phosphatidylinositol 3-kinase class 3 (PI3KC3) com-
plex to inhibit apoptosis and increase drug resistance
[32]. Most cancer therapies, such as radiation and anti-
cancer drugs, induce cancer cells to undergo autophagy
[48,49], which is an important mechanism of resistance
to therapy; thus, mechanisms involving HMGB1 might
be key regulators of resistance to anti-cancer therapies.
Furthermore, nuclear HMGB1 regulates HSPB1 gene ex-
pression. Mitophagy is responsible for the elimination of
dysfunctional and impaired mitochondria. It is unclear
whether or how mitophagy triggered by dysfunctional
mitochondria is regulated by nuclear mediators. How-
ever, it has been recognized that HMGB1 modulates
mitochondrial respiration and morphological features by
helping to sustain autophagy in mitochondrial mainten-
ance through regulation of HSPB1 gene expression [46].
Autophagy and mitophagy, therefore, are involved in
sustaining mitochondrial respiration and morphological
features after cellular stress and mitochondrial injury.
These mechanisms of nuclear HMGB1, including DNA
repair, and regulation of autophagy and mitophagy, might
be involved in the development of resistance of rectal
cancer cells to CRT. Thus, targeting of HMGB1 may be a
promising approach for the development of novel thera-
peutic strategies for rectal cancer.
In our series, however, no significant correlation
between HMGB1 expression and recurrence-free or
overall survival was found. Since HMGB1 is reported
to have paradoxical effects on tumor progression by af-
fecting both the cancer cells and the tumor immunity,
the counter-balance between these two effects may be
important in determining the final effect. However,
caution is required in interpreting our present data.
HMGB1 could not be identified as an effective predict-
ive factor for CRT, because only tumor tissues ob-
tained after CRT were used for immunohistochemical
staining of HMGB1, and immunostaining of HMGB1
may be affected by CRT itself. Another limitation wasthe small number of patients, and the retrospective
nature of the study.
Conclusions
In conclusion, using immunohistochemistry, this study
demonstrated the association of HMGB1 expression in
human rectal cancer tissue exposed to CRT with tumor
invasiveness and resistance to therapy. HMGB1, which
regulates both cell death and cell survival, likely plays a
role in the development of carcinogenesis and chemore-
sistance. Further large-scale prospective studies with long-
term follow-up periods, evaluating samples obtained pre-
and post-CRT, are needed to determine the potential
role of HMGB1 as a prognostic factor for CRT in rectal
cancer.
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